首页> 美国卫生研究院文献>other >Increased Risk of Q151M and K65R Mutations in Patients Failing Stavudine-Containing First-Line Antiretroviral Therapy in Cambodia
【2h】

Increased Risk of Q151M and K65R Mutations in Patients Failing Stavudine-Containing First-Line Antiretroviral Therapy in Cambodia

机译:柬埔寨含司他夫定的一线抗逆转录病毒治疗失败的患者增加Q151M和K65R突变的风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMulti-nucleos(t)ide resistance (MNR) mutations including Q151M, K65R mutations, and insertion at codon 69 of HIV-1 reverse transcriptase coding region may confer resistance to all molecules of nucleos(t)ide reverse transcriptase inhibitors (NRTI). The presence of these mutations is an emerging problem compromising non-nucleoside reverse transcriptase inhibitors and protease inhibitors-based therapies. Furthermore, factors associated with selection of these mutations are still not well defined. The current study aimed to evaluate the frequency and to characterize factors associated with the occurrence of multi-nucleos(t)ide resistance mutations among HIV-1 infected patients failing recommended first-line antiretroviral regimens in Cambodia.
机译:背景多核苷酸抗(MNR)突变,包括Q151M,K65R突变以及在HIV-1逆转录酶编码区的69号密码子处插入,可赋予所有核苷酸逆转录酶抑制剂(NRTI)耐药性。这些突变的存在是新出现的问题,危及非核苷类逆转录酶抑制剂和基于蛋白酶抑制剂的疗法。此外,与这些突变的选择相关的因素仍然没有很好地定义。当前的研究旨在评估在推荐的一线抗逆转录病毒治疗方案未通过柬埔寨接受HIV-1感染的患者中发生多核苷酸(t)耐药性突变的频率并确定其相关因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号